Could a Low-Dose ketamine infusion beat MS fatigue?
NCT ID NCT05378100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a single low-dose ketamine infusion can reduce fatigue in people with multiple sclerosis. About 110 adults with MS-related fatigue will receive either ketamine or a mild sedative (midazolam) as a placebo. The study measures changes in fatigue scores over time to see if ketamine offers meaningful relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ketamine
What this could lead to
If it works, this could point toward a new treatment option for fatigue in multiple sclerosis, improving daily energy and quality of life.
What could go wrong
This is a small, early-phase trial (110 people) with an active placebo, so results may not be conclusive. Ketamine can cause side effects like dizziness or dissociation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States